PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-31.28%
Negative net income growth while GNPX stands at 35.71%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
1.30%
Less D&A growth vs. GNPX's 10.23%, reducing the hit to reported earnings. David Dodd would confirm that core assets remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
41.15%
SBC growth while GNPX is negative at -67.23%. John Neff would see competitor possibly controlling share issuance more tightly.
170.16%
Slight usage while GNPX is negative at -156.71%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
170.16%
Some yoy usage while GNPX is negative at -157.99%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
169.42%
Some yoy increase while GNPX is negative at -100.00%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-4.39%
Both yoy CFO lines are negative, with GNPX at -27.08%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
94.15%
Some CapEx rise while GNPX is negative at -2222.38%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Investing outflow well above GNPX's 104.72%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
-97.06%
Negative yoy issuance while GNPX is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.